
Benjamin J Solomon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8645620/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer. New England Journal of Medicine, 2010, 363, 1693-1703.	27.0	4,141
2	Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer. New England Journal of Medicine, 2013, 368, 2385-2394.	27.0	3,181
3	First-Line Crizotinib versus Chemotherapy in <i>ALK</i> -Positive Lung Cancer. New England Journal of Medicine, 2014, 371, 2167-2177.	27.0	2,808
4	Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor <i>EML4-ALK</i> . Journal of Clinical Oncology, 2009, 27, 4247-4253.	1.6	1,775
5	Crizotinib in <i>ROS1</i> -Rearranged Non–Small-Cell Lung Cancer. New England Journal of Medicine, 2014, 371, 1963-1971.	27.0	1,656
6	Comprehensive genomic profiles of small cell lung cancer. Nature, 2015, 524, 47-53.	27.8	1,634
7	Ceritinib in <i>ALK</i> -Rearranged Non–Small-Cell Lung Cancer. New England Journal of Medicine, 2014, 370, 1189-1197.	27.0	1,367
8	Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nature Genetics, 2012, 44, 1104-1110.	21.4	1,186
9	Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncology, The, 2012, 13, 1011-1019.	10.7	1,176
10	Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers. Science Translational Medicine, 2012, 4, 120ra17.	12.4	1,138
11	Lung cancer. Lancet, The, 2021, 398, 535-554.	13.7	896
12	Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncology, The, 2011, 12, 1004-1012.	10.7	847
13	Rociletinib in <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer. New England Journal of Medicine, 2015, 372, 1700-1709.	27.0	615
14	First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i> -Positive Lung Cancer. New England Journal of Medicine, 2020, 383, 2018-2029.	27.0	592
15	Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncology, The, 2018, 19, 1654-1667.	10.7	587
16	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Archives of Pathology and Laboratory Medicine, 2018, 142, 321-346.	2.5	586
17	Clinical Experience With Crizotinib in Patients With Advanced <i>ALK</i> -Rearranged Non–Small-Cell Lung Cancer and Brain Metastases. Journal of Clinical Oncology, 2015, 33, 1881-1888.	1.6	555
18	Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncology, The, 2017, 18, 1590-1599.	10.7	535

#	ARTICLE Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and	IF	CITATIONS
19	Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. Advances in Anatomic Pathology, 2017, 24.	4.3	530
20	311-335. Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer. New England Journal of Medicine, 2020, 383, 813-824.	27.0	505
21	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. Advances in Anatomic	4.3	469
22	Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers. New England Journal of Medicine, 2020, 383, 825-835.	27.0	454
23	Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncology, The, 2016, 17, 452-463.	10.7	418
24	Updated Molecular Testing Guideline for theÂSelection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology, 2018, 13, 323-358.	1.1	408
25	Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification. Journal of Thoracic Oncology, 2011, 6, 942-946.	1.1	407
26	<i>MET</i> Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib. Journal of Clinical Oncology, 2011, 29, 4803-4810.	1.6	404
27	Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. Lancet Oncology, The, 2019, 20, 494-503.	10.7	386
28	An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer. Cancer Cell, 2019, 36, 385-401.e8.	16.8	359
29	Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments. Seminars in Cancer Biology, 2018, 52, 228-240.	9.6	314
30	Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 2251-2258.	1.6	308
31	Mass Spectrometry to Classify Non–Small-Cell Lung Cancer Patients for Clinical Outcome After Treatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Multicohort Cross-Institutional Study. Journal of the National Cancer Institute, 2007, 99, 838-846.	6.3	303
32	ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2009, 4, 1450-1454.	1.1	297
33	Targeting Anaplastic Lymphoma Kinase in Lung Cancer. Clinical Cancer Research, 2011, 17, 2081-2086.	7.0	282
34	<i>ALK</i> Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2019, 37, 1370-1379.	1.6	282
35	Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. Nature Medicine, 2020, 26, 47-51.	30.7	255
36	Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors. Nature Communications, 2018, 9, 1048.	12.8	254

#	Article	IF	CITATIONS
37	Rationale for co-targeting IGF-1R and ALK in ALK fusion–positive lung cancer. Nature Medicine, 2014, 20, 1027-1034.	30.7	243
38	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors. Journal of Molecular Diagnostics, 2018, 20, 129-159.	2.8	241
39	Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. Nature Communications, 2014, 5, 3518.	12.8	239
40	<i>CD74–NRG1</i> Fusions in Lung Adenocarcinoma. Cancer Discovery, 2014, 4, 415-422.	9.4	238
41	Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial. Lancet Oncology, The, 2019, 20, 1691-1701.	10.7	233
42	Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced <i>ALK</i> -Positive Non–Small-Cell Lung Cancer: Results From PROFILE 1014. Journal of Clinical Oncology, 2016, 34, 2858-2865.	1.6	216
43	RET Solvent Front Mutations Mediate AcquiredÂResistance to Selective RET Inhibition inÂRET-Driven Malignancies. Journal of Thoracic Oncology, 2020, 15, 541-549.	1.1	189
44	Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib. Clinical Cancer Research, 2015, 21, 2745-2752.	7.0	173
45	Assessment of <i>EGFR</i> Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686). Clinical Cancer Research, 2016, 22, 2386-2395.	7.0	169
46	Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Modern Pathology, 2013, 26, 1545-1553.	5.5	138
47	The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment. Frontiers in Immunology, 2016, 7, 621.	4.8	132
48	Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer Treated with Erlotinib. Clinical Cancer Research, 2011, 17, 3304-3315.	7.0	126
49	Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity. Nature Immunology, 2020, 21, 914-926.	14.5	114
50	EGFR blockade with ZD1839 ("lressaâ€) potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. International Journal of Radiation Oncology Biology Physics, 2003, 55, 713-723.	0.8	110
51	Managing haematology and oncology patients during the <scp>COVID</scp> â€19 pandemic: interim consensus guidance. Medical Journal of Australia, 2020, 212, 481-489.	1.7	107
52	COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nature Reviews Clinical Oncology, 2021, 18, 313-319.	27.6	103
53	Crizotinib and Testing for ALK. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 1335-1341.	4.9	102
54	Clinical Management of Adverse Events Associated with Lorlatinib. Oncologist, 2019, 24, 1103-1110.	3.7	101

#	Article	IF	CITATIONS
55	Supercharging adoptive T cell therapy to overcome solid tumor–induced immunosuppression. Science Translational Medicine, 2019, 11, .	12.4	100
56	Crizotinib in <i>ROS1</i> -Rearranged Non–Small-Cell Lung Cancer. New England Journal of Medicine, 2015, 372, 683-684.	27.0	99
57	CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy. Nature Communications, 2021, 12, 3236.	12.8	99
58	Prognostic Significance of PD-L1+ and CD8+ Immune Cells in HPV+ Oropharyngeal Squamous Cell Carcinoma. Cancer Immunology Research, 2018, 6, 295-304.	3.4	93
59	First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma. Journal of Clinical Neuroscience, 2015, 22, 1889-1894.	1.5	88
60	Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer. ESMO Open, 2017, 2, e000219.	4.5	87
61	Relationship between Epidermal Growth Factor Receptor Status, p16INK4A, and Outcome in Head and Neck Squamous Cell Carcinoma. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1230-1237.	2.5	84
62	Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2013, 8, 940-946.	1.1	78
63	Rapid and Dramatic Radiographic and Clinical Response to an ALK Inhibitor (Crizotinib, PF02341066) in an ALK Translocation-Positive Patient with Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 2044-2046.	1.1	73
64	Comparison of Methods in the Detection of ALK and ROS1 Rearrangements in Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 611-618.	1.1	70
65	Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol. Thyroid, 2019, 29, 1634-1645.	4.5	69
66	Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors. Journal of Clinical Oncology, 2020, 38, 2140-2150.	1.6	68
67	A community-based model of rapid autopsy in end-stage cancer patients. Nature Biotechnology, 2016, 34, 1010-1014.	17.5	66
68	Lung cancer prognostic index: a risk score to predict overall survival after the diagnosis of non-small-cell lung cancer. British Journal of Cancer, 2017, 117, 744-751.	6.4	66
69	Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs. Cancer Research, 2015, 75, 4211-4223.	0.9	65
70	Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement Journal of Clinical Oncology, 2012, 30, 7508-7508.	1.6	65
71	Advanced-Stage Non–Small Cell Lung Cancer: Advances in Thoracic Oncology 2018. Journal of Thoracic Oncology, 2019, 14, 1134-1155.	1.1	61
72	Inhibition of DNA-Dependent Protein Kinase Induces Accelerated Senescence in Irradiated Human Cancer Cells. Molecular Cancer Research, 2011, 9, 1696-1707.	3.4	60

#	Article	IF	CITATIONS
73	Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. Annals of Oncology, 2021, 32, 620-630.	1.2	60
74	An inverse stageâ€shift model to estimate the excess mortality and health economic impact of delayed access to cancer services due to the COVIDâ€19 pandemic. Asia-Pacific Journal of Clinical Oncology, 2021, 17, 359-367.	1.1	59
75	A First-Time-In-Human Phase I Clinical Trial of Bispecific Antibody-Targeted, Paclitaxel-Packaged Bacterial Minicells. PLoS ONE, 2015, 10, e0144559.	2.5	58
76	Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non–Small Cell Lung Cancer: Results of a Phase I Study. Journal of Thoracic Oncology, 2016, 11, 737-747.	1.1	54
77	Differential mechanisms of <i>CDKN2A</i> (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcome. International Journal of Cancer, 2014, 135, 887-895.	5.1	53
78	Rheumatic immune-related adverse events secondary to anti–programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. European Journal of Cancer, 2018, 105, 88-102.	2.8	53
79	Radiotherapy and immunotherapy: a synergistic effect in cancer care. Medical Journal of Australia, 2019, 210, 47-53.	1.7	53
80	Safety and efficacy of lorlatinib (PF-06463922) from the dose-escalation component of a study in patients with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC) Journal of Clinical Oncology, 2016, 34, 9009-9009.	1.6	53
81	Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer. Cancer Research and Treatment, 2018, 50, 691-700.	3.0	50
82	IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors. Molecular Therapy, 2020, 28, 2379-2393.	8.2	49
83	Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging. Molecular Cancer Therapeutics, 2005, 4, 1417-1422.	4.1	48
84	Complex renal cysts associated with crizotinib treatment. Cancer Medicine, 2015, 4, 887-896.	2.8	47
85	Avelumab (anti–PD-L1) in combination with crizotinib or lorlatinib in patients with previously treated advanced NSCLC: Phase 1b results from JAVELIN Lung 101 Journal of Clinical Oncology, 2018, 36, 9008-9008.	1.6	47
86	An Open-Label, Single-Arm Phase Two Trial of Gefitinib in Patients With Advanced or Metastatic Castration-Resistant Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 338-341.	1.3	46
87	Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer. Lung Cancer, 2020, 146, 310-317.	2.0	46
88	Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data. Genome Biology, 2015, 16, 7.	8.8	44
89	First-line crizotinib versus pemetrexed–cisplatin or pemetrexed–carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014). Journal of Clinical Oncology, 2014, 32, 8002-8002.	1.6	44
90	Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With <i>ALK</i> -Positive Advanced Non–Small-Cell Lung Cancer From the Phase III CROWN Study. Journal of Clinical Oncology, 2022, 40, 3593-3602.	1.6	43

#	Article	IF	CITATIONS
91	Detection of the transforming AKT1 mutation E17K in non-small cell lung cancer by high resolution melting. BMC Research Notes, 2008, 1, 14.	1.4	42
92	Suicide in Lung Cancer. Chest, 2013, 144, 1245-1252.	0.8	42
93	Efficacy and safety of crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC) Journal of Clinical Oncology, 2013, 31, 8032-8032.	1.6	42
94	Ceritinib in patients with advanced anaplastic lymphoma kinase–rearranged anaplastic large-cell lymphoma. Blood, 2015, 126, 1257-1258.	1.4	40
95	p16â€positive lymph node metastases from cutaneous head and neck squamous cell carcinoma: No association with highâ€risk human papillomavirus or prognosis and implications for the workup of the unknown primary. Cancer, 2016, 122, 1201-1208.	4.1	40
96	Scientific Advances in Thoracic Oncology 2016. Journal of Thoracic Oncology, 2017, 12, 1183-1209.	1.1	40
97	BRAF Inhibition in <i>BRAF</i> ^{V600E} -Positive Anaplastic Thyroid Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 249-254.	4.9	38
98	A critical re-assessment of DNA repair gene promoter methylation in non-small cell lung carcinoma. Scientific Reports, 2014, 4, 4186.	3.3	37
99	Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer. Journal of Thoracic Disease, 2013, 5 Suppl 5, S579-92.	1.4	37
100	Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations. Molecular Cancer Therapeutics, 2021, 20, 2446-2456.	4.1	35
101	Differential ¹⁸ F-FDG and 3′-Deoxy-3′- ¹⁸ F-Fluorothymidine PET Responses to Pharmacologic Inhibition of the c-MET Receptor in Preclinical Tumor Models. Journal of Nuclear Medicine, 2011, 52, 1261-1267.	5.0	33
102	Assessment of postâ€mortemâ€induced changes to the mouse brain proteome. Journal of Neurochemistry, 2008, 105, 725-737.	3.9	32
103	Everolimus in Combination with Pemetrexed in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with Chemotherapy: A Phase I Study Using a Novel, Adaptive Bayesian Dose-Escalation Model. Journal of Thoracic Oncology, 2011, 6, 2120-2129.	1.1	32
104	Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors. Drugs, 2019, 79, 1277-1286.	10.9	32
105	Class IA Phosphatidylinositol 3-Kinase Signaling in Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2009, 4, 787-791.	1.1	30
106	Frequency of Fibroblast Growth Factor Receptor 1 gene amplification in oral tongue squamous cell carcinomas and associations with clinical features and patient outcome. Oral Oncology, 2013, 49, 576-581.	1.5	30
107	Dynamic Thromboembolic Risk Modelling to Target Appropriate Preventative Strategies for Patients with Non-Small Cell Lung Cancer. Cancers, 2019, 11, 50.	3.7	30
108	Evaluation of an artificial intelligence clinical trial matching system in Australian lung cancer patients. JAMIA Open, 2020, 3, 209-215.	2.0	30

#	Article	IF	CITATIONS
109	TP53 Status, Patient Sex, and the Immune Response as Determinants of Lung Cancer Patient Survival. Cancers, 2020, 12, 1535.	3.7	30
110	Phase III study of selpercatinib versus chemotherapy ±Âpembrolizumab in untreated <i>RET</i> positive non-small-cell lung cancer. Future Oncology, 2021, 17, 763-773.	2.4	30
111	Treatment of ALK-positive nonsmall cell lung cancer: recent advances. Current Opinion in Oncology, 2018, 30, 84-91.	2.4	29
112	New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer. Current Treatment Options in Oncology, 2015, 16, 49.	3.0	28
113	A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer. Lung Cancer, 2020, 142, 34-40.	2.0	27
114	Clinical Benefit From Pemetrexed Before and After Crizotinib Exposure and From Crizotinib Before and After Pemetrexed Exposure in Patients With Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2013, 14, 636-643.	2.6	25
115	Sex-Dependent Staging in Non–Small-Cell Lung Cancer; Analysis of the Effect of Sex Differences in the Eighth Edition of the Tumor, Node, Metastases Staging System. Clinical Lung Cancer, 2018, 19, e933-e944.	2.6	24
116	EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non–Small Cell Lung Cancer. Clinical Lung Cancer, 2021, 22, e859-e869.	2.6	23
117	Progress in Molecular Targeted Therapy for Thyroid Cancer: Vandetanib in Medullary Thyroid Cancer. Journal of Clinical Oncology, 2012, 30, 119-121.	1.6	22
118	Co-targeting Deoxyribonucleic Acid–Dependent Protein Kinase and Poly(Adenosine) Tj ETQq0 0 0 rgBT /Overlo International Journal of Radiation Oncology Biology Physics, 2014, 88, 385-394.	ock 10 Tf 5 0.8	50 387 Td (Dip 22
119	First-Line Crizotinib in <i>ALK</i> -Positive Lung Cancer. New England Journal of Medicine, 2015, 372, 781-782.	27.0	22
120	Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma. Molecular Cancer Therapeutics, 2017, 16, 1610-1622.	4.1	22
121	Living with and beyond metastatic non-small cell lung cancer: the survivorship experience for people treated with immunotherapy or targeted therapy. Journal of Cancer Survivorship, 2021, 15, 392-397.	2.9	22
122	Adjuvant Chemotherapy for Non-Small Cell Lung Cancer. Cancer Investigation, 2007, 25, 217-225.	1.3	20
123	Absence of a Relationship between Tumor 18F-fluorodeoxyglucose Standardized Uptake Value and Survival in Patients Treated with Definitive Radiotherapy for Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2014, 9, 377-382.	1.1	20
124	The Influence of Comorbidity and the Simplified Comorbidity Score on Overall Survival in Non–Small Cell Lung Cancer—A Prospective Cohort Study. Journal of Thoracic Oncology, 2016, 11, 748-757.	1.1	20
125	Clinicopathologic Features of NSCLC Diagnosed During Pregnancy or the Peripartum Period in the Era of Molecular Genotyping. Journal of Thoracic Oncology, 2016, 11, 1522-1528.	1.1	20
126	Efficacy and safety of lorlatinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) with one or more prior ALK tyrosine kinase inhibitor (TKI): A phase I/II study Journal of Clinical Oncology, 2017, 35, 9006-9006.	1.6	20

#	Article	IF	CITATIONS
127	Spleen Volume Variation in Patients with Locally Advanced Non-Small Cell Lung Cancer Receiving Platinum-Based Chemo-Radiotherapy. PLoS ONE, 2015, 10, e0142608.	2.5	20
128	The emerging era of personalized therapy in squamous cell carcinoma of the head and neck. Asia-Pacific Journal of Clinical Oncology, 2011, 7, 236-251.	1.1	19
129	Quantitative methodology is critical for assessing DNA methylation and impacts on correlation with patient outcome. Clinical Epigenetics, 2014, 6, 22.	4.1	19
130	Crizotinib Associated Renal Cysts [CARCs]: incidence and patterns of evolution. Cancer Imaging, 2017, 17, 7.	2.8	19
131	Abiraterone in Metastatic Salivary Duct Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 288-290.	4.9	18
132	Impact of COVID-19 on cancer service delivery: results from an international survey of oncology clinicians. ESMO Open, 2020, 5, e001090.	4.5	18
133	Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES). , 2021, 9, e002995.		18
134	Targeted therapy for advanced anaplastic lymphoma kinase (<i>ALK</i>)-rearranged non-small cell lung cancer. The Cochrane Library, 2022, 2022, CD013453.	2.8	18
135	Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions. Drugs, 2015, 75, 1059-1070.	10.9	17
136	Validation and characterisation of prognostically significant PD-L1+ immune cells in HPV+ oropharyngeal squamous cell carcinoma. Oral Oncology, 2020, 101, 104516.	1.5	17
137	Clinical characteristics of ALK+ NSCLC patients (pts) treated with crizotinib beyond disease progression (PD): Potential implications for management Journal of Clinical Oncology, 2012, 30, 7600-7600.	1.6	17
138	A phase I and biodistribution study of ABT-806i, an ¹¹¹ indium-labeled conjugate of the tumor-specific anti-EGFR antibody ABT-806 Journal of Clinical Oncology, 2013, 31, 2520-2520.	1.6	17
139	Validating <i>ROS1</i> Rearrangements As a Therapeutic Target in Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2015, 33, 972-974.	1.6	16
140	Phase lb/ll study of the PI3Kα inhibitor BYL719 in combination with cetuximab in recurrent/metastatic squamous cell cancer of the head and neck (SCCHN) Journal of Clinical Oncology, 2014, 32, 6044-6044.	1.6	16
141	Prevalence, morphology, and natural history of FGFR1-amplified lung cancer, including squamous cell carcinoma, detected by FISH and SISH. Modern Pathology, 2014, 27, 1621-1631.	5.5	15
142	Thromboembolism in Anaplastic Lymphoma Kinase–Rearranged Non–Small Cell Lung Cancer. Clinical Lung Cancer, 2018, 19, e71-e72.	2.6	14
143	Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer. Lung Cancer, 2020, 144, 10-19.	2.0	14
144	Patients Treated With Platinum-Doublet Chemotherapy for Advanced Non–Small-Cell Lung Cancer Have Inferior Outcomes If Previously Treated With Platinum-based Chemoradiation. Clinical Lung Cancer, 2013, 14, 508-512.	2.6	13

#	Article	IF	CITATIONS
145	Lung Cancer in Australia. Journal of Thoracic Oncology, 2020, 15, 1809-1814.	1.1	13
146	Updated overall efficacy and safety of selpercatinib in patients (pts) with <i>RET</i> fusion+ non-small cell lung cancer (NSCLC) Journal of Clinical Oncology, 2021, 39, 9065-9065.	1.6	13
147	Survival difference according to mutation status in a prospective cohort study of Australian patients with metastatic nonâ€smallâ€cell lung carcinoma. Internal Medicine Journal, 2018, 48, 37-44.	0.8	12
148	Correlation between molecular analysis, diagnosis according to the 2015 WHO classification of unresected lung tumours and TTF1 expression in small biopsies and cytology specimens from 344 non-small cell lung carcinoma patients. Pathology, 2017, 49, 604-610.	0.6	11
149	Impact of COVID-19 on cancer service delivery: a follow-up international survey of oncology clinicians. ESMO Open, 2021, 6, 100224.	4.5	11
150	Sex and SUVmax: Sex-Dependent Prognostication in Early Non–Small Cell Lung Cancer. Journal of Nuclear Medicine, 2012, 53, 1676-1685.	5.0	10
151	Correlation of Ataxia-Telangiectasia-Mutated (ATM) gene loss with outcome in head and neck squamous cell carcinoma. Oral Oncology, 2012, 48, 698-702.	1.5	10
152	Refining the Toxicity Profile of Crizotinib. Journal of Thoracic Oncology, 2014, 9, 1596-1597.	1.1	10
153	DNA repair pathways and their therapeutic potential in lung cancer. Lung Cancer Management, 2014, 3, 159-173.	1.5	10
154	A New Theranostic Paradigm for Advanced Thyroid Cancer. Journal of Nuclear Medicine, 2016, 57, 1493-1494.	5.0	10
155	Impact of sex on prognostic host factors in surgical patients with lung cancer. ANZ Journal of Surgery, 2017, 87, 1015-1020.	0.7	10
156	Patient-reported quality of life and toxicity in unilateral and bilateral radiotherapy for early-stage human papillomavirus associated tonsillar carcinoma. Clinical and Translational Radiation Oncology, 2020, 21, 85-90.	1.7	10
157	Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial. Lung Cancer, 2022, 169, 67-76.	2.0	10
158	Trials and Tribulations of EGFR and MET Inhibitor Combination Therapy in NSCLC. Journal of Thoracic Oncology, 2017, 12, 9-11.	1.1	9
159	Alectinib induces marked red cell spheroacanthocytosis in a near-ubiquitous fashion and is associated with reduced eosin-5-maleimide binding. Pathology, 2021, 53, 608-612.	0.6	9
160	Genome-scale methylation assessment did not identify prognostic biomarkers in oral tongue carcinomas. Clinical Epigenetics, 2016, 8, 74.	4.1	8
161	<i>EGFR</i> Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non–Small-Cell Lung Cancer Treated With Rociletinib, an <i>EGFR</i> Tyrosine Kinase Inhibitor. JCO Precision Oncology, 2018, 2, 1-13.	3.0	8
162	Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer. Pathology, 2019, 51, 673-680.	0.6	8

#	Article	IF	CITATIONS
163	Promising Immuno-Oncology Options for the Future: Cellular Therapies and Personalized Cancer Vaccines. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e253-e258.	3.8	8
164	A Phase 1 and Biodistribution Study of ABT-806i, an ¹¹¹ In-Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806. Journal of Nuclear Medicine, 2021, 62, 787-794.	5.0	8
165	First-line treatment options for ALK -rearranged lung cancer. Lancet, The, 2017, 389, 884-886.	13.7	7
166	Immunotherapy in oncogene addicted non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 2736-2751.	2.8	7
167	Novel RET Fusion <i>RET-SEPTIN9</i> Predicts Response to Selective RET Inhibition With Selpercatinib in Malignant Pheochromocytoma. JCO Precision Oncology, 2021, 5, 1160-1165.	3.0	7
168	Local ablative therapies in oligometastatic NSCLC-upfront or outback?—a narrative review. Translational Lung Cancer Research, 2021, 10, 3446-3456.	2.8	7
169	Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease. Journal of Thoracic Oncology, 2022, 17, 568-577.	1.1	7
170	Are Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer Prognostic, Predictive, or Both?. Journal of Thoracic Oncology, 2012, 7, 5-7.	1.1	6
171	Molecular Therapeutic Advances in Personalized Therapy of Melanoma and Non-Small Cell Lung Cancer. Journal of Personalized Medicine, 2012, 2, 35-49.	2.5	6
172	Preoperative chemotherapy for non-small-cell lung cancer. Lancet, The, 2014, 384, 232-233.	13.7	6
173	Immunotherapy for Anaplastic Thyroid Carcinoma. Journal of Clinical Oncology, 2020, 38, 2603-2604.	1.6	6
174	960MO Clinical outcomes and immune responses in a phase I/II study of personalized, neoantigen-directed immunotherapy in patients with advanced MSS-CRC, GEA and NSCLC. Annals of Oncology, 2021, 32, S830-S831.	1.2	6
175	A randomized double-blind trial of carboplatin plus paclitaxel (CP) with daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo (PLA) in patients (pts) with previously untreated advanced non-small cell lung cancer (NSCLC):Â NCIC Clinical Trials Group study BR29 Journal of Clinical Oncology, 2012, 30, 7511-7511.	1.6	6
176	Visual effects in anaplastic lymphoma kinase (<i>ALK</i>)-positive advanced non-small cell lung cancer (NSCLC) patients treated with crizotinib Journal of Clinical Oncology, 2012, 30, 7596-7596.	1.6	6
177	Biology and Treatment Advances in Cutaneous Squamous Cell Carcinoma. Cancers, 2021, 13, 5645.	3.7	6
178	EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma. Medical Oncology, 2017, 34, 175.	2.5	5
179	Targeting platelets for improved outcome in KRAS-driven lung adenocarcinoma. Oncogene, 2020, 39, 5177-5186.	5.9	5
180	Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival. Npj Precision Oncology, 2021, 5, 33.	5.4	5

#	Article	IF	CITATIONS
181	Gemcitabine plus docetaxel for advanced or metastatic non-small cell lung cancer: Similar survival to cisplatin plus vinorelbine and less toxicity. Cancer Treatment Reviews, 2005, 31, 571-576.	7.7	4
182	Editor in Chief: Response to EyreetÂal. "ALK-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease― European Journal of Haematology, 2015, 94, 86-87.	2.2	4
183	Prospective Study of Cetuximab, Carboplatin, and Radiation Therapy for Patients With Locally Advanced Head and Neck Squamous Cell Cancer Unfit for Cisplatin. International Journal of Radiation Oncology Biology Physics, 2017, 98, 948-954.	0.8	4
184	Validation of local p16 testing for determination of human papilloma virus status eligibility on a low risk oropharyngeal cancer trial – A Trans-Tasman Radiation Oncology Group study. Oral Oncology, 2020, 110, 104988.	1.5	4
185	Defining resistance mechanisms to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer. Annals of Oncology, 2020, 31, 1599-1600.	1.2	4
186	Mesenchyme to epithelial transition protein expression, gene copy number and clinical outcome in a large non-small cell lung cancer surgical cohort. Translational Lung Cancer Research, 2019, 8, 167-175.	2.8	4
187	Finding chinks in the osimertinib resistance armor. Translational Lung Cancer Research, 2020, 9, 2173-2177.	2.8	3
188	Progression-free survival with subsequent anticancer therapies from a phase 3 trial of lorlatinib in treatment-naive patients (pts) with <i>ALK</i> + advanced non–small cell lung cancer (NSCLC) Journal of Clinical Oncology, 2022, 40, 9069-9069.	1.6	3
189	Imaging of molecular target modulation in oncology: challenges of early clinical trials. Clinical and Translational Imaging, 2014, 2, 5-12.	2.1	2
190	Genomic Characterization of Lung Cancer and Its Impact on the Use and Timing of PET in Therapeutic Response Assessment. PET Clinics, 2018, 13, 33-42.	3.0	2
191	Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer. The Cochrane Library, 0, , .	2.8	2
192	1199P Dose modification for the management of CNS adverse events in the phase III CROWN study of lorlatinib in non-small cell lung cancer (NSCLC). Annals of Oncology, 2021, 32, S957-S958.	1.2	2
193	Clinical benefit from pemetrexed before and after crizotinib exposure in patients with ALK positive non-small cell lung cancer (ALK+ NSCLC) Journal of Clinical Oncology, 2012, 30, 7601-7601.	1.6	2
194	Subgroup analysis of crizotinib versus either pemetrexed (PEM) or docetaxel (DOC) in the phase III study (PROFILE 1007) of advanced ALK-positive non-small cell lung cancer (NSCLC) Journal of Clinical Oncology, 2013, 31, 8105-8105.	1.6	2
195	Abstract CT025: Impact of the EML4-ALK fusion variant on the efficacy of lorlatinib in patients (pts) with ALK-positive advanced non-small cell lung cancer (NSCLC). , 2020, , .		2
196	Crizotinib for the treatment of non-small-cell lung cancer withALKgene rearrangements. Clinical Investigation, 2012, 2, 895-907.	0.0	1
197	Response to Mahe. Modern Pathology, 2014, 27, 1424-1425.	5.5	1
198	Ophthalmological assessment of crizotinib in advanced non-small-cell lung cancer. Lung Cancer, 2020, 145, 167-172.	2.0	1

#	Article	IF	CITATIONS
199	Reply to "Emergence of High Level of MET Amplification During Treatment With Selpercatinib in KIF5B-RET NSCLC― Journal of Thoracic Oncology, 2020, 15, e127-e128.	1.1	1
200	Standard-Dose Osimertinib in EGFR-Mutated Non–Small-Cell Lung Adenocarcinoma With Leptomeningeal Disease. JCO Precision Oncology, 2021, 5, 561-568.	3.0	1
201	Identification of good and poor prognosis HPV associated oropharyngeal cancer based on CD103 immune cell expression in patients treated with cetuximab and radiotherapy on TROG 12.01 and De-ESCALaTE randomized trials Journal of Clinical Oncology, 2021, 39, 109-109.	1.6	1
202	Response to selpercatinib versus prior systemic therapy in patients (pts) with RET fusion+ non-small-cell lung cancer (NSCLC) Journal of Clinical Oncology, 2021, 39, 9032-9032.	1.6	1
203	O10-3 Selpercatinib (LOXO-292) in patients (pts) with RET-altered thyroid cancer. Annals of Oncology, 2021, 32, S289.	1.2	1
204	Functional and patientâ€reported changes in swallowing and voice after combined chemotherapy and radiotherapy for limitedâ€stage smallâ€cell lung cancer. Journal of Medical Imaging and Radiation Oncology, 2021, 65, 786-795.	1.8	1
205	Pitfalls and progress in adrenocortical carcinoma diagnosis: the utility of a multidisciplinary approach, immunohistochemistry and genomics. Endocrinology, Diabetes and Metabolism Case Reports, 2022, 2022, .	0.5	1
206	M06-03: Prediction of benefit from EGFR TKIs by proteomic analysis of pretreatment serum. Journal of Thoracic Oncology, 2007, 2, S167-S168.	1.1	0
207	In Replay: Psychiatric Morbidity in Patients with Lung Cancer. Chest, 2014, 145, 666.	0.8	0
208	Navigating Through New, First-Line Treatment Options for Lung Cancer. Journal of Oncology Practice, 2018, 14, 539-540.	2.5	0
209	Identifying Mechanisms of Resistance to ALK Tyrosine Kinase Inhibitors Using Analysis of Circulating Tumor DNA. Journal of Thoracic Oncology, 2020, 15, 482-484.	1.1	0
210	<scp>Nuclear protein in testis</scp> carcinoma: a diagnostic and therapeutic challenge. Internal Medicine Journal, 2021, 51, 1191-1192.	0.8	0
211	Complete metabolic response following anaplastic lymphoma kinase (<scp>ALK)</scp> targeted therapy in a patient with adenocarcinoma of unknown primary with immunohistochemistry/fluorescence <scp><i>in situ</i></scp> hybridisation discordant <scp>ALK</scp> test results. Internal Medicine lournal, 2021, 51, 1355-1356.	0.8	0
212	Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancer. Future Oncology, 2021, 17, 4649-4656.	2.4	0
213	1196P Pre-existing and acquired mechanisms of resistance to lorlatinib in previously treated patients (pts) with ALK+ advanced non-small cell lung cancer (NSCLC). Annals of Oncology, 2021, 32, S955.	1.2	0
214	Weekly cisplatin and radiotherapy for low-risk human papillomavirus positive oropharyngeal squamous cell carcinoma (HPVOPC) Journal of Clinical Oncology, 2014, 32, e17017-e17017.	1.6	0
215	Risk assessment model potency to detect patients most likely to benefit from thromboprophylaxis: An application of the TARGET-TP score Journal of Clinical Oncology, 2022, 40, 12116-12116.	1.6	0